Want to see SEPN full AI Analyst Report?
Top Page
Septerna, Inc.
(NASDAQ:SEPN)
Select Model
Select Model
Rating:61Neutral
Price Target:
$38.00
▲(14.80% Upside)
Action:Reiterated
Date:07/08/26
The score is driven primarily by improving financial trajectory (notably the shift to strong positive operating and free cash flow and a low-leverage balance sheet), supported by a technically constructive uptrend. Offsetting these positives are continued sizable operating losses and a negative P/E, while recent corporate events add moderate upside via early clinical progress.
Positive Factors
Improved Cash Generation
Septerna's shift to strongly positive operating and free cash flow is a durable improvement in cash generation and discipline. This reduces near-term financing dependence, supports continued R&D funding and trial execution, and materially lowers liquidity risk versus prior years.
Negative Factors
Ongoing Operating Losses
Despite top-line acceleration, persistent operating and net losses mean Septerna has yet to demonstrate sustainable profitability. Continued losses can erode capital, pressure returns, and may necessitate external funding if cash generation weakens or R&D spending ramps.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Cash Generation
Septerna's shift to strongly positive operating and free cash flow is a durable improvement in cash generation and discipline. This reduces near-term financing dependence, supports continued R&D funding and trial execution, and materially lowers liquidity risk versus prior years.
Read all positive factors
Septerna, Inc. (SEPN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.59B
Dividend YieldN/A
Average Volume (3M)489.97K
Price to Earnings (P/E)―
Beta (1Y)2.05
Revenue Growth7295.60%
EPS Growth58.57%
CountryUS
Employees130
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding45,075,535
10 Day Avg. Volume335,874
30 Day Avg. Volume489,971
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.23
Price to Sales (P/S)26.85
P/FCF Ratio11.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$48.17Price Target Upside45.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$76.98M
Septerna, Inc. Business Overview & Revenue Model
Company Description
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1...
How the Company Makes Money
null...
Septerna, Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 72.25M | 45.95M | 1.07M | 151.00K | 0.00 |
| Gross Profit | 71.83M | 45.95M | 1.07M | 151.00K | 0.00 |
| EBITDA | -52.12M | -47.26M | -70.89M | -44.70M | -27.39M |
| Net Income | -36.04M | -48.88M | -71.80M | 4.18M | -27.68M |
Balance Sheet | |||||
| Total Assets | 569.69M | 596.19M | 456.55M | 130.87M | 36.12M |
| Cash, Cash Equivalents and Short-Term Investments | 347.40M | 391.09M | 350.92M | 88.48M | 30.61M |
| Total Debt | 23.09M | 23.63M | 25.48M | 12.57M | 710.00K |
| Total Liabilities | 191.23M | 214.26M | 36.51M | 169.24M | 80.32M |
| Stockholders Equity | 378.46M | 381.93M | 420.05M | -38.37M | -44.20M |
Cash Flow | |||||
| Free Cash Flow | 106.93M | 109.67M | -69.57M | -41.60M | -24.59M |
| Operating Cash Flow | 107.90M | 110.19M | -67.47M | -38.72M | -23.30M |
| Investing Cash Flow | -248.29M | -229.35M | -160.60M | 22.12M | -1.29M |
| Financing Cash Flow | 1.96M | 1.69M | 377.78M | 74.52M | 30.05M |
Septerna, Inc. Technical Analysis
Positive
33.10
Price Trends
33.30
Positive
29.08
Positive
27.25
Positive
Market Momentum
0.07
Positive
48.08
Neutral
51.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEPN, the sentiment is Positive. The current price of 33.1 is below the 20-day moving average (MA) of 34.24, below the 50-day MA of 33.30, and above the 200-day MA of 27.25, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 51.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SEPN.
Septerna, Inc. Risk Analysis
Septerna, Inc. disclosed 89 risk factors in its most recent earnings report. Septerna, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Septerna, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $873.31M | 7.45 | 43.85% | ― | 68.20% | ― | |
61 Neutral | $1.59B | -42.53 | -9.44% | ― | 7295.60% | 58.57% | |
59 Neutral | $1.74B | -9.06 | -44.72% | ― | -15.35% | 37.09% | |
56 Neutral | $826.49M | -2.69 | -141.95% | ― | 5.37% | -60.20% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | $87.16M | -0.21 | 174.85% | ― | -55.42% | -248.85% |
* General Sector Average
SEPN
Septerna, Inc.
34.45
22.24
182.15%
TBPH
Theravance Biopharma
16.86
5.96
54.68%
KURA
Kura Oncology
9.01
2.99
49.67%
GOSS
Gossamer Bio
0.17
-1.83
-91.55%
MRVI
Maravai Lifesciences Holdings
6.57
4.35
195.95%
Septerna, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Septerna Shareholders Elect Directors, Ratify Ernst & Young
Positive
Jun 30, 2026
At its annual meeting of stockholders held on June 26, 2026, Septerna, Inc. reported that shareholders elected Shalini Sharp and Jake Simson as Class II directors to the Board for three‑year terms ending in 2029, with both to serve until suc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.